Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bharat Damle

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 24, 2009
Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative womenJulie B Dumond, Kristine B Patterson, Allison L Pecha, et al.
British Journal of Clinical Pharmacology|May 15, 2023
Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adultsDonna S Cox, Lien Van Eyck, Sylvester Pawlak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancerSteven J Cohen, Cynthia G Leichman, Gwen Yeslow, et al.
Clinical Pharmacology and Therapeutics|August 19, 2023
Patient Centric Microsampling to Support Paxlovid Clinical Development: Bridging and ImplementationKatty Wan, Olga Kavetska, Bharat Damle, et al.
The New England Journal of Medicine|February 16, 2022
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19Jennifer Hammond, Heidi Leister-Tebbe, Annie Gardner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five daysJame Abraham, Manish Agrawal, Susan Bakke, et al.
Clinical Pharmacology and Therapeutics|June 17, 2022
Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal ImpairmentSima S Toussi, Joel Michael Neutel, Jesus Navarro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignanciesQuincy Siu-Chung Chu, Lisa A Hammond, Garry Schwartz, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 24, 2009
Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative womenJulie B Dumond, Kristine B Patterson, Allison L Pecha, et al.
British Journal of Clinical Pharmacology|May 15, 2023
Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adultsDonna S Cox, Lien Van Eyck, Sylvester Pawlak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancerSteven J Cohen, Cynthia G Leichman, Gwen Yeslow, et al.
Clinical Pharmacology and Therapeutics|August 19, 2023
Patient Centric Microsampling to Support Paxlovid Clinical Development: Bridging and ImplementationKatty Wan, Olga Kavetska, Bharat Damle, et al.
The New England Journal of Medicine|February 16, 2022
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19Jennifer Hammond, Heidi Leister-Tebbe, Annie Gardner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five daysJame Abraham, Manish Agrawal, Susan Bakke, et al.
Clinical Pharmacology and Therapeutics|June 17, 2022
Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal ImpairmentSima S Toussi, Joel Michael Neutel, Jesus Navarro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignanciesQuincy Siu-Chung Chu, Lisa A Hammond, Garry Schwartz, et al.
Pageof 4